Genzyme Announces Multi-Year Multiple Sclerosis Research Collaboration with Leading Academic Medical Center
Wednesday, April 30, 2014 11:30 am EDT
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today the formation of a research collaboration with Cleveland Clinic focused on developing new therapeutic approaches to the treatment of MS.
This innovative collaboration aligns the research efforts of both organizations around projects which are designed to develop a deep understanding of the pathogenesis and progression of MS and to address the unmet medical needs in MS, particularly progressive forms of the disease. Initially the collaboration will focus on projects that explore strategies to address neurodegeneration, a hallmark of progressive MS, and novel technologies to better understand the pathology of the disease. The collaboration will be led by a joint steering committee comprised of Genzyme and Cleveland Clinic researchers and span a minimum of 5 years.
As leaders in MS we want to advance and build a sustainable pipeline of novel therapeutic approaches, and our collaboration with Cleveland Clinic, along with our internal R&D efforts, reinforce Genzyme’s long-term commitment to the MS community,
said David Meeker, President and CEO, Genzyme. We are excited to work collaboratively with a premier research and health care institution that has made many important contributions to better understanding this complex and devastating disease.
Cleveland Clinic’s Mellen Center for Multiple Sclerosis has one of the largest and most comprehensive programs for MS care and research worldwide, managing more than 20,000 patient visits every year. The Center has a highly innovative and active research team, which has been at the forefront of MS advances for the past two decades.
This collaboration will allow for the development of innovative approaches to evaluate potential new therapies for progressive MS,
said Dr. Jeffrey Cohen, M.D., Director of the Experimental Therapeutics Program at the Mellen Center for Multiple Sclerosis.
More than 2.3 million people worldwide have been diagnosed with MS, including approximately 400,000 people in the United States.
About Genzyme, a Sanofi Company
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.
Genzyme® is a registered trademark.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words expects
, anticipates
, believes
, intends
, estimates
, plans
and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forwardlooking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under Risk Factors
and Cautionary Statement Regarding Forward-Looking Statements
in Sanofi’s annual report on Form 20-F for the year ended December 31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
Contact:
Genzyme Media Relations
Erin Walsh, + 1 617-768-6881
erin.walsh@genzyme.com
or
Sanofi Investor Relations
Kristen Galfetti, +1 908-981-5560
ir@sanofi.com
